"Leukemia, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
| Descriptor ID |
D015448
|
| MeSH Number(s) |
C04.557.337.428.080 C15.604.515.560.080 C20.683.515.528.080
|
| Concept/Terms |
Leukemia, B-Cell- Leukemia, B-Cell
- Leukemia, B Cell
- Lymphocytic Leukemia, B-Cell
- B-Cell Lymphocytic Leukemia
- B-Cell Lymphocytic Leukemias
- Leukemia, B-Cell Lymphocytic
- Leukemias, B-Cell Lymphocytic
- Lymphocytic Leukemia, B Cell
- Lymphocytic Leukemias, B-Cell
- Leukemia, Lymphocytic, B Cell
- Leukemia, Lymphocytic, B-Cell
- B-Cell Leukemia
- B Cell Leukemia
- B-Cell Leukemias
- Leukemias, B-Cell
- B-Lymphocytic Leukemia
- B Lymphocytic Leukemia
- B-Lymphocytic Leukemias
- Leukemia, B-Lymphocytic
- Leukemias, B-Lymphocytic
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, B-Cell".
This graph shows the total number of publications written about "Leukemia, B-Cell" by people in this website by year, and whether "Leukemia, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 4 | 0 | 4 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2010 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leukemia, B-Cell" by people in Profiles.
-
MUC4 expression by immunohistochemistry is a specific marker for BCR-ABL1+ and BCR-ABL1-like B-lymphoblastic leukemia. Leuk Lymphoma. 2022 06; 63(6):1436-1444.
-
Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. Haematologica. 2018 06; 103(6):1065-1072.
-
Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci. 2015 Sep 05; 370(1676).
-
Stem cell factor expression in B cell malignancies is influenced by the niche. Leuk Lymphoma. 2013 Oct; 54(10):2274-80.
-
Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia. 2010 Nov; 24(11):1844-51.
-
Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis. Blood. 2010 Oct 14; 116(15):2759-67.
-
The role of late/slow replication of the FRA16D in common fragile site induction. Genes Chromosomes Cancer. 2004 Jan; 39(1):71-6.
-
Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to upregulate antitumor effects and downregulate antihost responses. Bone Marrow Transplant. 2003 Sep; 32(5):495-504.
-
Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study. Leuk Lymphoma. 2002 Dec; 43(12):2335-41.
-
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003 Jan 01; 101(1):6-14.